Adicet Bio opened lower at $2.96, compared with its previous close of $2.99. In the last trading session, the stock traded between $2.84 and $3.08. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in Adicet Bio is now worth
$ 1.92
Resulting in a loss of
$ 98.08 (98.08%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.05 (-1.77%)
Day High
$3.08
Day Low
$2.84
Day Open
$2.96
Prev Close
$2.99
Volume
3,13,606
1W Return
-4.80%
1M Return
-47.11%
3M Return
-64.44%
6M Return
-64.05%
1Y Return
-71.59%
Fundamentals
Market Cap ($ Mn)
28
PE Ratio
-
PB Ratio
0.70
PEG Ratio
-
ROE
-77.89%
ROCE
-75.28%
EPS (TTM)
$-2.02
Investment Returns
1 Week
-4.80%
1 Month
-47.11%
3 Months
-64.44%
6 Months
-64.05%
9 Months
-56.87%
Financials
Quarterly
All values in $ Mn
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Mar 26
0.0
Jun 26
0.0
Sep 26
Updates
6Nov
Guggenheim lowers Adicet Bio price target to $55, keeps Buy
Guggenheim lowered Adicet Bio's price target from $90 to $55. Analyst Yatin Suneja maintained a Buy rating on the stock. The price target cut represents a $35 reduction in projected value.
6 days ago
6Nov
Adicet Bio Q3 Results: Loss widens to $1.76 per share, misses estimates
Adicet Bio posted a Q3 loss of $1.76 per share. The result missed the analyst consensus estimate of $1.59 by 10.69%. Losses increased 62.07% YoY from $4.64 per share in the prior year.
7 days ago
1Oct
Adicet Bio grants inducement stock options to new hire under Nasdaq rule
Adicet Bio granted 725 non-qualified stock options to a new hire on September 30, 2026. Exercise price set at $7.14 per share, matching the Nasdaq closing price on grant date. Award issued under Nasdaq Listing Rule 5635(c)(4) via the 2022 Inducement Plan. Vesting includes a one-year cliff followed by 36 monthly installments over four years.
1mo ago
28Sep
Adicet Bio reports 54% remission in prula-cel lupus Phase 1 study
54% of evaluable patients achieved DORIS remission at 12 months. 50% of lupus nephritis patients achieved complete renal response. All patients discontinued immunosuppressants; one patient on steroids >5 mg. Pivotal trial start-up planned for Q4 2026 for lupus nephritis. Potential expansion to non-nephritis SLE patients under discussion.
1mo ago
18Sep
HC Wainwright reiterates Buy on Adicet Bio, keeps $27 target
HC Wainwright & Co. reiterates a Buy rating on Adicet Bio. Analyst Robert Burns maintains the price target at $27. The stock trades on NASDAQ under ticker ACET.
1mo ago
1Sep
Adicet Bio grants 1,500 stock options to new hire at $8.70
Adicet Bio granted 1,500 non-qualified stock options to a new hire. Exercise price set at $8.70 per share, matching closing price on August 31, 2026. Award authorized under Nasdaq Listing Rule 5635(c)(4) as material inducement. Options vest over four years with 25% cliff and monthly installments thereafter. Grant made under the 2022 Inducement Plan, bypassing stockholder approval.
